Back

Daewon Pharmaceutical completes Fadoprazan ERD trial enrollment, targets November data

Verifying
  • Daewon Pharmaceutical completed enrollment for Fadoprazan's Phase 3 ERD trial.
  • 370 billion won is the annual prescription value of South Korea's domestic P-CAB market.
  • Daewon plans November topline results and a December application to the Ministry of Food and Drug Safety.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.